InterMune Inc (ITMN)

73.89
0.02 0.03
NASDAQ : Health Care
Prev Close 73.91
Open 73.91
Day Low/High 73.81 / 73.99
52 Wk Low/High 10.95 / 74.24
Volume 5.72M
Avg Volume 3.94M
Exchange NASDAQ
Shares Outstanding 107.97M
Market Cap 7.98B
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Why Roche (RHHBY) Stock Is Up Today

Why Roche (RHHBY) Stock Is Up Today

CEO Schwan told Reuters that the company's decision to buy U.S. biotech company InterMune (ITMN) was "exceptional" and not a sign of more ambitious plans for major acquisitions.

Why Anxious Investors' Pressure Could Push Small Cap Stocks Lower

Why Anxious Investors' Pressure Could Push Small Cap Stocks Lower

Small-cap stocks are experiencing selling pressure this week as volatility rises as world event prey on investor uncertainty.

InterMune Larger Than S&P 500 Component D.R. Horton

InterMune Larger Than S&P 500 Component D.R. Horton

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component InterMune Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example D.

INTERMUNE SHAREHOLDER ALERT – InterMune, Inc.: The Law Offices Of Vincent Wong Investigates The Sale Of InterMune, Inc. To Roche Holding AG

INTERMUNE SHAREHOLDER ALERT – InterMune, Inc.: The Law Offices Of Vincent Wong Investigates The Sale Of InterMune, Inc. To Roche Holding AG

The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of InterMune, Inc.

INTERMUNE INVESTOR ALERT: Faruqi & Faruqi, LLP Is Investigating The Board Of Directors Of InterMune, Inc. (ITMN) In Relation To The Proposed Sale Of The Company To Roche Holdings, Inc.

INTERMUNE INVESTOR ALERT: Faruqi & Faruqi, LLP Is Investigating The Board Of Directors Of InterMune, Inc. (ITMN) In Relation To The Proposed Sale Of The Company To Roche Holdings, Inc.

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of InterMune, Inc.

Roche, InterMune a Strategic Play in Midst of Inversions

Roche, InterMune a Strategic Play in Midst of Inversions

As more companies seek tax savings through inversions, strategic reasons still remain for drug company deals.

INVESTOR ALERT – InterMune, Inc.: The Law Offices Of Vincent Wong Investigates The Sale Of InterMune, Inc. To Roche Holding AG

INVESTOR ALERT – InterMune, Inc.: The Law Offices Of Vincent Wong Investigates The Sale Of InterMune, Inc. To Roche Holding AG

The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of InterMune, Inc.

Why InterMune (ITMN) Stock Is Gaining Today

Why InterMune (ITMN) Stock Is Gaining Today

InterMune (ITMN) shares are up on heavy trading, one day after the company agreed to be bought by Roche for $8.3 billion.

Jim Cramer's 'Mad Money' Recap: Thank You, Corporate America

Jim Cramer's 'Mad Money' Recap: Thank You, Corporate America

Corporate profits, not the Fed, are fueling ever higher stock prices, and that growth is only accelerating, Cramer says.

INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of InterMune, Inc. Over The Proposed Sale Of The Company To Roche Holdings, Inc. - ITMN

INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of InterMune, Inc. Over The Proposed Sale Of The Company To Roche Holdings, Inc. - ITMN

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Intermune, Inc.

Summer Rally Contiues on Lower Volume

Summer Rally Contiues on Lower Volume

We remain in a strong market that has yet to show any sign of stopping.

SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of InterMune, Inc. In Connection With The Proposed Sale Of The Company To Roche Holdings, Inc.

SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of InterMune, Inc. In Connection With The Proposed Sale Of The Company To Roche Holdings, Inc.

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of...

Why InterMune (ITMN) Stock Soared to a One-Year High Today

Why InterMune (ITMN) Stock Soared to a One-Year High Today

InterMune (ITMN) soared to a 52-week high of $73.19 on Monday after Swiss-based company Roche Holding announced it would buy the biotechnology company for $8.3 billion.

Stock Market Today: Stocks Get Juiced as Yellen Argues for Labor Expansion

Stock Market Today: Stocks Get Juiced as Yellen Argues for Labor Expansion

The S&P 500 smashes its way through 2,000 on Monday after a minor pullback, bolstering the case that the current rally will continue.

3 Huge stocks to Trade (or Not)

3 Huge stocks to Trade (or Not)

Here's how to trade some of the most active stocks on the market today.

Five Billionaire-Owned Biotech Stocks You Could Acquire for 100%

Five Billionaire-Owned Biotech Stocks You Could Acquire for 100%

These five stocks all have the potential to be acquired for a 100% premium or more, and each are heavily owned by a top hedge fund or billionaire...

Biotechs Rise After InterMune Acquired by Roche

Biotechs Rise After InterMune Acquired by Roche

Shares of a number of biopharmaceutical companies are climbing after drug maker Roche agreed to buy its smaller peer, Intermune, developer of treatments for respiratory and orphan fibrotic diseases.

Why Jim Cramer Thinks Merck (MRK), Pfizer (PFE), GlaxoSmithKline (GSK) Bids Are Coming After InterMune (ITMN) Deal

Why Jim Cramer Thinks Merck (MRK), Pfizer (PFE), GlaxoSmithKline (GSK) Bids Are Coming After InterMune (ITMN) Deal

TheStreet's Jim Cramer explains why the InterMune (ITMN) deal means big pharma is thinking big.